V Mohan1,2, N M Bruin1,2, M E T Tesselaar3, J P de Boer3, E Vegt1,4, J J M A Hendrikx1,5, A Al-Mamgani1, J B van de Kamer1, J-J Sonke1, W V Vogel6,7. 1. Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. 2. Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 3. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. 5. Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 6. Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands. w.vogel@nki.nl. 7. Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands. w.vogel@nki.nl.
Abstract
RATIONALE: Salivary glands are highly perfused and express the prostate-specific membrane antigen (PSMA) receptor as well as the sodium-iodide symporter. As a consequence, treatment with 177Lu/225Ac-PSMA for prostate cancer or 131I for thyroid cancer leads to a high radiation dose in the salivary glands, and patients can be confronted with persistent xerostomia and reduced quality of life. Salivation can be inhibited using an antimuscarinic pharmaceutical, such as glycopyrronium bromide (GPB), which may also reduce perfusion. The primary objective of this work was to determine if inhibition with GPB could provide a considerable (> 30%) reduction in the accumulation of administered 123I or 68Ga-PSMA-11 in salivary glands. METHODS: Ten patients who already received a whole-body 68Ga-PSMA-11 PET/CT scan for (re)staging of prostate cancer underwent a repeat PET/CT scan with tracer administration at 90 min after intravenous injection of 0.2 mg GPB. Four patients in follow-up after thyroid cancer, who had been treated with one round of ablative 131I therapy with curative intent and had no signs of recurrence, received 123I planar scintigraphy at 4 h after tracer administration without GPB and a repeated scan at least one week later, with tracer administration at 30 min after intramuscular injection of 0.4 mg GPB. Tracer uptake in the salivary glands was quantified on PET and scintigraphy, respectively, and values with and without GPB were compared. RESULTS: No significant difference in PSMA uptake in the salivary glands was seen without or with GPB (Mean SULmean parotid glands control 5.57, intervention 5.72, p = 0.50. Mean SULmean submandibular glands control 6.25, intervention 5.89, p = 0.12). Three out of 4 patients showed increased 123I uptake in the salivary glands after GPB (Mean counts per pixel control 8.60, intervention 11.46). CONCLUSION: Muscarinic inhibition of salivation with GPB did not significantly reduce the uptake of PSMA-ligands or radioiodine in salivary glands, and can be dismissed as a potential strategy to reduce toxicity from radionuclide therapies.
RATIONALE: Salivary glands are highly perfused and express the prostate-specific membrane antigen (PSMA) receptor as well as the sodium-iodide symporter. As a consequence, treatment with 177Lu/225Ac-PSMA for prostate cancer or 131I for thyroid cancer leads to a high radiation dose in the salivary glands, and patients can be confronted with persistent xerostomia and reduced quality of life. Salivation can be inhibited using an antimuscarinic pharmaceutical, such as glycopyrronium bromide (GPB), which may also reduce perfusion. The primary objective of this work was to determine if inhibition with GPB could provide a considerable (> 30%) reduction in the accumulation of administered 123I or 68Ga-PSMA-11 in salivary glands. METHODS: Ten patients who already received a whole-body 68Ga-PSMA-11 PET/CT scan for (re)staging of prostate cancer underwent a repeat PET/CT scan with tracer administration at 90 min after intravenous injection of 0.2 mg GPB. Four patients in follow-up after thyroid cancer, who had been treated with one round of ablative 131I therapy with curative intent and had no signs of recurrence, received 123I planar scintigraphy at 4 h after tracer administration without GPB and a repeated scan at least one week later, with tracer administration at 30 min after intramuscular injection of 0.4 mg GPB. Tracer uptake in the salivary glands was quantified on PET and scintigraphy, respectively, and values with and without GPB were compared. RESULTS: No significant difference in PSMA uptake in the salivary glands was seen without or with GPB (Mean SULmean parotid glands control 5.57, intervention 5.72, p = 0.50. Mean SULmean submandibular glands control 6.25, intervention 5.89, p = 0.12). Three out of 4 patients showed increased 123I uptake in the salivary glands after GPB (Mean counts per pixel control 8.60, intervention 11.46). CONCLUSION: Muscarinic inhibition of salivation with GPB did not significantly reduce the uptake of PSMA-ligands or radioiodine in salivary glands, and can be dismissed as a potential strategy to reduce toxicity from radionuclide therapies.
Authors: Krista M D La Perle; Dong Chul Kim; Nathan C Hall; Adam Bobbey; Daniel H Shen; Rebecca S Nagy; Paul E Wakely; Amy Lehman; David Jarjoura; Sissy M Jhiang Journal: Thyroid Date: 2013-07-17 Impact factor: 6.568
Authors: Esther N Klein Hesselink; Adrienne H Brouwers; Johan R de Jong; Anouk N A van der Horst-Schrivers; Rob P Coppes; Joop D Lefrandt; Piet L Jager; Arjan Vissink; Thera P Links Journal: J Nucl Med Date: 2016-06-23 Impact factor: 10.057
Authors: Kristell L S Chatalic; Sandra Heskamp; Mark Konijnenberg; Janneke D M Molkenboer-Kuenen; Gerben M Franssen; Marian C Clahsen-van Groningen; Margret Schottelius; Hans-Jürgen Wester; Wytske M van Weerden; Otto C Boerman; Marion de Jong Journal: Theranostics Date: 2016-04-12 Impact factor: 11.556
Authors: Yoshihisa Kinoshita; Katsuyuki Kuratsukuri; Steve Landas; Katsumi Imaida; Peter M Rovito; Ching Y Wang; Gabriel P Haas Journal: World J Surg Date: 2006-04 Impact factor: 3.282
Authors: Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-26 Impact factor: 9.236